August 12, 2025
Read
August 12, 2025

Why GLP-1 Patches Don’t Deliver—Yet

Reviewed By:
Why GLP-1 Patches Don’t Deliver—Yet

Contents

Table of contents placeholder

TikTok’s GLP-1 patches are trending in the UK, but they’re not what they seem. Despite claims of “Ozempic in a sticker,” these patches do not contain licensed medications. Most include herbal stimulants and lack any scientific backing. This article breaks down why semaglutide cannot currently be delivered through skin, what the MHRA says about such products, and how to choose safe, evidence-based obesity treatments in the UK.

How GLP-1 drugs like Ozempic work 

After you eat, a hormone called GLP-1 is released by your gut1. This causes your pancreas to release insulin and, importantly, helps your body to tell your brain “I’m full”. Ozempic, which is a brand name for a drug called semaglutide, is what’s known as a GLP-1 receptor agonist, meaning it mimics the action of GLP-12

GLP-1 drugs were initially developed to help treat type 2 diabetes by regulating insulin release3. However, it has become well known for its ability to reduce feelings of hunger. GLP-1 drugs have been shown to support sustained weight loss by reducing appetite and food intake4

Why can’t semaglutide be absorbed through the skin?

Your skin forms a protective barrier to prevent harmful pathogens and molecules from entering your body. The size of molecules can be measured in Daltons, and typically only molecules smaller than 500 Daltons have any chance of entering through the skin and into the bloodstream5

Nicotine, for example, is around 162 Daltons and can therefore be absorbed into the bloodstream via nicotine patches6. Semaglutide, on the other hand, is over 4000 Daltons and is unlikely to be absorbed through the skin7

What’s in TikTok’s “GLP-1” patches? 

Products sold as “GLP-1” patches do not contain GLP-1 or GLP-1 analogues (similar molecules). Instead, they contain ingredients that they claim help your body produce GLP-1 naturally, such as caffeine, berberine, and other herbal extracts. While there is evidence that some ingredients may promote GLP-1 production in the body8,9, there is little evidence that these can reduce body fat long-term10.

UK Regulation and Consumer Safety 

No MHRA approval for GLP-1 patches 

GLP-1 patches are not authorised by the UK’s Medicines and Healthcare products Regulatory Agency (MHRA). This means that any product labelled as a “GLP-1” patch does not contain any active GLP-1. Companies that use names like Ozempic on herbal products are misleading customers and potentially breaking the law.

Dangers of unlicensed weight loss products 

Unlicensed weight loss products have not undergone rigorous safety testing, and you cannot be sure of the ingredients or dosing11. They can also interfere with prescribed medicines or cause health issues, such as skin burns or an elevated heart rate.

Official guidance from UK health authorities 

The National Institute for Health and Care Excellence (NICE) recommends GLP-1 drugs for patients with type 2 diabetes or with a very high BMI12. Semaglutide and other GLP-1 drugs can cause side effects like nausea, diarrhoea, dizziness, stomach pain, and constipation. Therefore, these medicines should only be prescribed by licensed providers after a thorough evaluation11

Safer, Science-Backed Approaches to Weight Loss 

How GLP-1 medications should be used 

The use of medicines like semaglutide, which significantly impact your body’s metabolism and food intake, should only be taken after medical screening and under monitoring by healthcare professionals. For example, Ozempic and Wegovy are injected weekly, and the dose is adjusted based on tolerance.

What real obesity care looks like 

Viral trends and fads are rarely a successful route to sustained and healthy weight loss. Weight loss management programs should focus on a personalised program of sustainable, healthy diet and regular physical activity. Where appropriate, cognitive behavioural therapy can help to control impulsive eating behaviours, while bariatric surgeries or injectable weight loss drugs might be recommended in urgent cases13.

How to spot red flags in weight loss products

There is an overwhelming amount of information about weight loss available online, making it hard to know who and what to trust. There are some red flags that you should look out for when making decisions about weight management.

  • Overpromising - for example, products promising you’ll “lose 10kg in a week”.
  • Products that are sold exclusively via social media, outside a healthcare environment.
  • Products that have not undergone clinical testing.
  • Products that promise weight loss without any change in diet or physical activity.

Ezra’s role in proactive health 

At Ezra, we believe that taking a science-first approach is the most reliable path to lasting health outcomes. Our full-body MRI scans can detect early organ changes and abnormalities before symptoms appear, including in the pancreas, liver, and other organs affected by weight and metabolic health.

This is a safe, non-invasive first step for anyone curious about their current health status or looking for a clear baseline before starting any lifestyle or medical intervention.

Book your Ezra UK scan today and gain a detailed, evidence-backed view of your inner health.

Summary: Health vs Hype

Many people exploring GLP-1 patches may be doing so out of frustration, stalled progress, or confusion about safe weight loss options. GLP-1 patches may be trending, but they’re not a medically recognised treatment. If you’re seeking effective weight loss support, trust evidence over online hype. Work with a GP, registered dietitian, or qualified medical weight management provider who can create a plan tailored to your needs and health history.

Want to understand your metabolic and hormonal health before committing to any treatment? An Ezra Full Body MRI gives you insight into up to 14 organs in under an hour. It’s non-invasive, safe, and could help guide smarter weight-related decisions.

Understand your risk for cancer with our 5 minute quiz.

Our scan is designed to detect potential cancer early.

References

1. Drucker DJ. Mechanisms of Action and Therapeutic Application of Glucagon-like Peptide-1. Cell Metab. 2018;27(4):740-756. doi:10.1016/j.cmet.2018.03.001 

2. Papakonstantinou I, Tsioufis K, Katsi V. Spotlight on the Mechanism of Action of Semaglutide. Curr Issues Mol Biol. 2024;46(12):14514-14541. doi:10.3390/cimb46120872 

3. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes | New England Journal of Medicine. Accessed August 12, 2025. https://www.nejm.org/doi/full/10.1056/NEJMoa1607141 

4. Wang JY, Wang QW, Yang XY, et al. GLP−1 receptor agonists for the treatment of obesity: Role as a promising approach. Front Endocrinol. 2023;14. doi:10.3389/fendo.2023.1085799 

5. Bos JD, Meinardi MM. The 500 Dalton rule for the skin penetration of chemical compounds and drugs. Exp Dermatol. 2000;9(3):165-169. doi:10.1034/j.1600-0625.2000.009003165.x 

6. PubChem. Nicotine. Accessed August 12, 2025. https://pubchem.ncbi.nlm.nih.gov/compound/89594 

7. PubChem. Semaglutide. Accessed August 11, 2025. https://pubchem.ncbi.nlm.nih.gov/compound/56843331 

8. McCarty MF. A chlorogenic acid-induced increase in GLP-1 production may mediate the impact of heavy coffee consumption on diabetes risk. Med Hypotheses. 2005;64(4):848-853. doi:10.1016/j.mehy.2004.03.037 

9. Xu JH, Liu XZ, Pan W, Zou DJ. Berberine protects against diet-induced obesity through regulating metabolic endotoxemia and gut hormone levels. Mol Med Rep. 2017;15(5):2765-2787. doi:10.3892/mmr.2017.6321 

10. Asbaghi O, Ghanbari N, Shekari M, et al. The effect of berberine supplementation on obesity parameters, inflammation and liver function enzymes: A systematic review and meta-analysis of randomized controlled trials. Clin Nutr ESPEN. 2020;38:43-49. doi:10.1016/j.clnesp.2020.04.010 

11. UK medicines regulator warns against buying weight loss medicines without a prescription this New Year. GOV.UK. Accessed August 11, 2025. https://www.gov.uk/government/news/uk-medicines-regulator-warns-against-buying-weight-loss-medicines-without-a-prescription-this-new-year 

12. GLP-1 receptor agonists | Prescribing information | Diabetes - type 2 | CKS | NICE. Accessed August 11, 2025. https://cks.nice.org.uk/topics/diabetes-type-2/prescribing-information/glp-1-receptor-agonists/ 

13. Obesity - Treatment. nhs.uk. October 23, 2017. Accessed August 11, 2025. https://www.nhs.uk/conditions/obesity/treatment/